| Identification | Back Directory | [Name]
KI-696 | [CAS]
1799974-70-1 | [Synonyms]
KI-696
KI-696,KI696
1H-Benzotriazole-5-propanoic acid, β-[3-[[(4R)-3,4-dihydro-4-methyl-1,1-dioxido-2H-5,1,2-benzoxathiazepin-2-yl]methyl]-4-methylphenyl]-7-methoxy-1-methyl-, (βS)- | [Molecular Formula]
C28H30N4O6S | [MDL Number]
MFCD31630709 | [MOL File]
1799974-70-1.mol | [Molecular Weight]
550.63 |
| Chemical Properties | Back Directory | [Boiling point ]
760.5±70.0 °C(Predicted) | [density ]
1.39±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 125 mg/mL (227.01 mM) | [form ]
Solid | [pka]
4.28±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Biological Activity]
KI-696 is a non-cytotoxic (10 mM; BEAS-2B cells)Kelch domain-targeing (Kd ~1.3 nM) KEAP1 selective inhibitor th at effectively upregulates nuclear NRF2 level in NHBE cells (%increase/[KI-696] = 100%/10 nM and 127%/100 nM; 6 hr) and NRF2 target genes transcription by blocking KEAP1-mediated NRF2 downregulation. KI-696 (5-50 mmol/kg i.v.) upregulates NRF2 target genes transcription in r at lungs in vivoas well as alleviate ozone-induced pulmonary inflammation and GSH depletion. KI-696 inhibits OATP1B1BSEPand PDE3A only at much higher concentrations (IC50 = 2.54.010 mMrespectively) and exhibits little or no potency toward a panel of 46 channelsenzymesand receptors. |
|
|